A61K 2239/55
Lung
A61K2239/55 (Lung) appears on 172 US grants and 458 published applications in this corpus.
Search patents in A61K- Granted patents
- 172
- Published applications
- 458
- Assignees
- 242
- Inventors
- 1,022
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 1 |
| 2002 | 1 | 3 |
| 2003 | 1 | 4 |
| 2004 | 1 | 5 |
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 3 |
| 2008 | 2 | 2 |
| 2009 | 0 | 6 |
| 2010 | 1 | 3 |
| 2011 | 1 | 2 |
| 2012 | 0 | 9 |
| 2013 | 1 | 3 |
| 2014 | 5 | 7 |
| 2015 | 4 | 6 |
| 2016 | 3 | 6 |
| 2017 | 3 | 14 |
| 2018 | 6 | 12 |
| 2019 | 7 | 25 |
| 2020 | 6 | 43 |
| 2021 | 11 | 58 |
| 2022 | 16 | 50 |
| 2023 | 21 | 53 |
| 2024 | 23 | 61 |
| 2025 | 35 | 38 |
| 2026 | 23 | 40 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Transforming growth factor beta-resistant natural killer cells8 Sep 2026US 12,729,228 B2Research Institute At Nationwide Children's Hospital
- Cell capable of activating immune system, and pharmaceutical composition containing said cell11 Aug 2026US 12,703,867 B2Riken
- Chimeric antigen receptors targeting CD127 and use thereof4 Aug 2026US 12,697,388 B2Memorial Sloan Kettering Cancer Center
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- Disruption of telocyte activity10 Sep 2026US 2026/0263514 A1
- Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors3 Sep 2026US 2026/0258120 A1St. Jude Children?S Research Hospital
- Method and drug for treating cancer by joint use of nkg2d chimeric antigen receptor and pd1 inhibitor27 Aug 2026US 2026/0248853 A1Daren Biotech Limited
- Gene-edited natural killer cells27 Aug 2026US 2026/0250634 A1Crispr Therapeutics AG
Most cited
By later US patents
- Compounds for therapy and diagnosis of lung cancer and methods for their use63US 6,444,425 B1Corixa Corporation · 2002
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010
- Compositions and methods for targeting stromal cells for the treatment of cancer49US 9,365,641 B2The Trustees of the University of Pennsylvania · 2016
- Antibody constructs for DLL3 and CD338US 10,294,300 B2Amgen Research (Munich) GmbH · 2019
- Transgenic macrophages, chimeric antigen receptors, and associated methods21US 10,415,017 B2Thunder Biotech Inc. · 2019